0002001011-25-000049.txt : 20250702 0002001011-25-000049.hdr.sgml : 20250702 20250702190342 ACCESSION NUMBER: 0002001011-25-000049 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221101 FILED AS OF DATE: 20250702 DATE AS OF CHANGE: 20250702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Espinoza Octavio CENTRAL INDEX KEY: 0001905248 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 251103187 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INC STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 3/A 1 edgardoc.xml PRIMARY DOCUMENT X0206 3/A 2022-11-01 2025-07-02 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001905248 Espinoza Octavio 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 Chief Financial Officer Common Stock 1696 D This amendment (the "Amendment") is being filed to correct the Form 3 filed with the Securities and Exchange Commission on November 1, 2022 (the "Original Form 3"), which inadvertently understated the Reporting Person's direct holdings of Ligand Pharmaceuticals, Inc. common stock ("Common Stock") by 1,696 shares. This Form 3/A is deemed to update the number of securities reported as beneficially owned in any Forms 4 subsequently filed by the reporting person through the date hereof. By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 2025-07-02